Education
About Us
Working with TipRanks
Follow Us
BrightSpring Health Services, Inc. (BTSG)
NASDAQ:BTSG
Top Page
BrightSpring Health Services, Inc.
(NASDAQ:BTSG)
Select Model
Select Model
Rating:69Neutral
Price Target:
$45.00
▲(8.62% Upside)
Action:ReiteratedDate:02/28/26
The score is driven by improved financial performance (profitability, free cash flow, and leverage repair) and constructive technical trend. These positives are tempered by expensive valuation (high P/E, no dividend yield provided) and execution risk from 2026 headwinds and integration/transition factors discussed on the earnings call.
Positive Factors
Free Cash Flow Strength
Sustained free cash flow near $490M in 2025 materially improves the company’s ability to fund operations, pay down debt, and invest in growth without reliance on external financing. Over a 2–6 month horizon, stronger FCF reduces liquidity risk and increases flexibility for M&A, execution of margin initiatives, and capital allocation.
Balance Sheet Repair / Lower Leverage
Marked leverage reduction and an expanded equity base signal materially lower financial risk versus recent years. A stronger balance sheet supports resilience to reimbursement shocks, funds integration costs, and enables targeted capital deployment (including planned divestiture proceeds to further delever). This durability improves credit flexibility and tolerance for strategic moves.
Scale and Momentum in Pharmacy Solutions
A large, fast-growing pharmacy franchise—driven by specialty, infusion, and an expanding LDD portfolio—creates durable revenue streams and operational scale advantages. High dispensing accuracy, on-time delivery, and ~149 LDDs with continued launches support sticky relationships, pricing leverage with payors, and recurring script volumes across complex patient populations.
Negative Factors
Structurally Thin Margins
Persistently low net and EBITDA margins limit the firm's buffer against reimbursement cuts or volume shocks and make cash flow highly sensitive to cost swings. Over a multi-month horizon, thin margins constrain reinvestment capacity, reduce room for integration missteps, and heighten reliance on procurement and efficiency programs to sustain profitability.
Material IRA and Brand-to-Generic Headwinds
Quantified regulatory and mix-driven revenue losses in the hundreds of millions represent a structural threat to pharmacy economics. These headwinds reduce top-line predictability and force the company to offset with procurement savings, dispensing fee increases, or volume growth—each of which takes time and may compress margins over an extended period.
Acquisition Integration & Lower Near-Term Margins
Acquired branches that earn below-company-average margins and the need for integration/technology investment create execution risk. Realizing projected synergies and margin accretion is timing-uncertain, potentially weighing on near-term profitability and extending the period before acquisitions meaningfully boost return on invested capital.
BrightSpring Health Services, Inc. (BTSG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.47B
Dividend YieldN/A
Average Volume (3M)4.71M
Price to Earnings (P/E)47.2
Beta (1Y)1.11
Revenue Growth17.23%
EPS GrowthN/A
CountryUS
Employees37,000
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.33
Shares Outstanding180,352,300
10 Day Avg. Volume4,742,774
30 Day Avg. Volume4,710,325
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)4.05
Price to Sales (P/S)0.59
P/FCF Ratio19.22
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue0.79
Enterprise Value/Gross Profit6.74
Enterprise Value/Ebitda22.25
Forecast
1Y Price Target
$46.00Price Target Upside11.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.33
Revenue Forecast (FY)$14.62B
BrightSpring Health Services, Inc. Business Overview & Revenue Model
Company DescriptionBrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. BrightSpring Health Services, Inc. was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. The company was founded in 1974 and is based in Louisville, Kentucky.
How the Company Makes MoneyBrightSpring Health Services generates revenue through multiple channels, primarily by providing direct care services to individuals through government contracts, private insurance reimbursements, and out-of-pocket payments from clients. Key revenue streams include Medicaid-funded services, which make up a significant portion of their income, as well as partnerships with healthcare providers and community organizations that enhance service delivery. Additionally, the company invests in technology solutions that improve operational efficiency and care outcomes, contributing to cost savings and revenue growth. Strategic alliances with healthcare systems and participation in value-based care models further bolster its financial performance.
BrightSpring Health Services, Inc. Earnings Call Summary
Earnings Call Date:Feb 27, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 01, 2026
Earnings Call Sentiment Positive
The call was predominantly positive: BrightSpring reported strong 2025 results with robust revenue (28% YoY) and EBITDA (34% YoY) growth, meaningful improvement in cash flow and leverage, high-quality operational metrics across business lines, and confident 2026 guidance (midpoint implying ~14% revenue and ~25% EBITDA growth). Management also outlined strategic M&A activity (Amedisys acquisition) and a pending Community Living divestiture expected to generate ~$715M of net proceeds to further reduce leverage. Offsetting these positives are notable near-term headwinds from IRA and brand-to-generic conversions (gross impacts quantified in the hundreds of millions), disruption from a large customer bankruptcy and exit of uneconomic customers, and integration/timing risk related to acquired assets. Overall, the highlights—strong growth, cash generation, margin expansion, and balance sheet improvement—outweigh the lowlights, which are being actively managed.Q4-2025 Updates
Positive Updates
Strong Top-Line and EBITDA Growth (2025)
Full year 2025 total revenue of $12.9B, representing 28% year-over-year growth; full year adjusted EBITDA of $618M, up 34% year over year. Fourth quarter revenue grew ~29% and adjusted EBITDA grew ~41% versus prior-year quarter.
Pharmacy Solutions Momentum
Pharmacy Solutions revenue of $11.4B for 2025 (31% YoY growth). Q4 pharmacy revenue grew 32% and adjusted EBITDA grew 44% YoY. Specialty & infusion revenue grew 43% in Q4; specialty and infusion script growth ~30% YoY in Q4. Total pharmacy script volume 10.8M in the quarter.
Provider Services Growth and Margin Expansion
Provider Services 2025 revenue $1.5B (11% YoY). Q4 provider revenue grew 13% YoY and segment adjusted EBITDA grew 16% with adjusted EBITDA margin of 16.4% (up ~50 basis points YoY). Home health revenue grew 19% and average daily census grew 15% to ~35,000 in Q4.
Cash Flow and Balance Sheet Improvement
Operating cash flow of $490M for 2025 (Q4 CFO $232M). Net debt $2.5B as of 12/31/2025. Leverage improved to 2.99x (down from 4.16x a year earlier) and management expects pro forma leverage of ~2.6x after Community Living divestiture; longer-term target of 2.5x or below.
Strategic M&A and Capital Deployment
Acquisition of 107 Amedisys branches for $239M (cash funded) generating pro forma revenue of $345M for 2025; expected contribution of ~$30M to 2026 adjusted EBITDA from Amedisys and LHC. Announced plan to divest Community Living with expected net after-tax proceeds of ~$715M to be used primarily for debt paydown.
Operational and Quality Achievements
Adjusted EBITDA margin expansion overall (4.8% for 2025, +20bps YoY). Strong quality and service metrics: home health >91% of branches 4+ stars and 99.4% timely initiation of care; hospice CAHPS overall rating 87% (top 5% program); dispensing accuracy 99.99%, order completeness 99.3%, on-time delivery 96.8%; infusion patient satisfaction 94%.
Ongoing Growth Drivers and Product Pipeline
LDD (limited distribution drug) portfolio at 149 LDDs with 24 launches in 2025 and 5 in Q4; company expects 16–20+ LDD launches over the next 12–18 months. Management cites continued drivers: new LDDs, generic utilization, fee-for-service growth, commercial execution and infusion expansion.
Forward Guidance for 2026
2026 guidance (continuing operations): total revenue $14.45B–$15.0B (implying ~11.9%–16.2% growth over 2025 excluding Community Living); total adjusted EBITDA $760M–$790M (23.1%–27.9% growth over 2025 excluding Community Living). Management expects ~14% revenue growth and ~25% adjusted EBITDA growth at the midpoints.
Negative Updates
Revenue Impact from IRA and Brand-to-Generic Conversions
Management disclosed material revenue headwinds from IRA and brand-to-generic conversions: specialty & infusion IRA revenue headwind ~ $200M; combined brand-to-generic + IRA impact in specialty & infusion a little over $400M; additional home & community IRA impact ~ $175M. Company stated there remain net headwinds to navigate in 2026.
Customer Bankruptcy and Contract Exits
Home and community pharmacy volumes declined ~1% in the quarter due to the unwinding of a large customer that declared bankruptcy and company-initiated exits of specific uneconomic customers. Management noted script challenges in home & community pharmacy persisting until roughly Q3 2026.
Integration Costs and Lower Near-Term Margin on Amedisys Assets
Amedisys assets acquired carry lower near-term margins (management described as roughly high single-digit on pro forma math) and the company expects integration and technology investments, travel and other transitional costs that may limit immediate margin accretion; timeline to reach company-average margins is uncertain.
Pharmacy Revenue Headwind Complexity and Guidance Sensitivity
Multiple moving parts (IRA, generics, customer transitions, and payer negotiations) create uncertainty in 2026 pharmacy revenue cadence. Management quantified gross headwinds but also referenced mitigations (enhanced dispensing fees, operational offsets), making net impact somewhat ambiguous in the transcript.
Short-Term Script and Volume Pressure
Home and community pharmacy scripts expected to be challenged year-over-year until about Q3 due to the prior-year lapping and customer unwind; some temporary disruption to revenue and volumes is expected in early 2026 (Q1 being a shorter quarter and typically lowest quarter by days).
Company Guidance
BrightSpring guided 2026 total revenue of $14.45B–$15.0B (Pharmacy Solutions $12.6B–$13.1B; Provider Services $1.85B–$1.90B), which represents ~11.9%–16.2% growth over 2025 (≈14% at the midpoint), and total adjusted EBITDA of $760M–$790M (≈23.1%–27.9% growth year‑over‑year, ≈25% at the midpoint), which includes an expected ~$30M EBITDA contribution from the Amedisys/LHC acquisition; guidance excludes Community Living and any not‑closed deals. Management flagged specific 2026 revenue headwinds—~$200M from IRA in specialty/infusion, a little over $400M total in specialty/infusion when including brand‑to‑generic conversions, and ~$175M IRA impact in home & community pharmacy—while forecasting broad‑based margin expansion from procurement and operational initiatives, 16–20+ LDD launches over the next 12–18 months, sequential quarterly growth through the year (Q1 is the shortest quarter), and home & community script pressures expected to normalize by ~Q3.BrightSpring Health Services, Inc. Financial Statement Overview
Summary
Financials show a clear 2025 rebound: net income turned positive, free cash flow improved sharply (operating and free cash flow ~$490M), and leverage has materially improved versus prior years. Offsets are decelerating revenue growth, structurally thin margins (net margin ~1.5%, EBITDA margin ~3.6%), and a history of cash-flow volatility.Income Statement
Revenue has grown consistently from 2020 to 2025 (with 2025 growth at ~4%), indicating steady demand, but growth has clearly decelerated versus earlier years. Profitability improved meaningfully in 2025 with positive net income (~$191M) after losses in 2022–2024, yet overall margins remain thin (2025 net margin ~1.5%, EBITDA margin ~3.6%). Gross margin has also trended down over time (from ~18–19% in 2020–2021 to ~11.8% in 2025), suggesting higher cost pressure or mix shift even as bottom-line results rebounded.66
Positive
Balance Sheet
Leverage improved sharply by 2025, with debt-to-equity falling to ~0.13 from very elevated levels in 2021–2023 (roughly ~4–6x), which materially reduces financial risk. Equity has also expanded versus the low point in 2023, supporting a healthier capital base. The key watch-out is that returns on equity were negative in 2022–2024 due to net losses, though 2025 shows a return to solid profitability (ROE ~10%), indicating balance-sheet repair is translating into improved earnings power.74
Positive
Cash Flow
Cash generation strengthened substantially in 2025 with operating cash flow of ~$490M and free cash flow of ~$490M, a major improvement from 2024 (low operating cash flow and negative free cash flow). Free cash flow also covered net income well in 2025 (free cash flow roughly in-line with earnings), supporting earnings quality. However, cash-flow performance has been volatile (including negative operating cash flow in 2022), and the reported operating cash flow coverage ratio remains relatively low in most years, which suggests cash conversion and working-capital dynamics still warrant monitoring.70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.91B | 11.27B | 8.83B | 7.72B | 6.70B |
| Gross Profit | 1.52B | 1.59B | 1.43B | 1.35B | 1.25B |
| EBITDA | 459.53M | 398.13M | 349.52M | 391.80M | 433.34M |
| Net Income | 190.67M | -18.06M | -154.60M | -53.91M | 49.80M |
Balance Sheet | |||||
| Total Assets | 6.41B | 5.93B | 5.53B | 5.44B | 5.51B |
| Cash, Cash Equivalents and Short-Term Investments | 88.37M | 61.25M | 13.07M | 13.63M | 46.73M |
| Total Debt | 2.84B | 2.90B | 3.67B | 3.68B | 3.77B |
| Total Liabilities | 4.53B | 4.27B | 4.92B | 4.66B | 4.71B |
| Stockholders Equity | 1.88B | 1.65B | 584.74M | 754.78M | 774.82M |
Cash Flow | |||||
| Free Cash Flow | 394.69M | -57.14M | 137.26M | -74.77M | 210.90M |
| Operating Cash Flow | 490.17M | 23.77M | 210.78M | -4.65M | 270.17M |
| Investing Cash Flow | -310.18M | -140.24M | -134.43M | 45.36M | -1.19B |
| Financing Cash Flow | -152.77M | 164.65M | -76.91M | -73.81M | 705.22M |
BrightSpring Health Services, Inc. Technical Analysis
Positive
41.43
Price Trends
38.99
Positive
35.99
Positive
29.68
Positive
Market Momentum
0.57
Negative
58.09
Neutral
65.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTSG, the sentiment is Positive. The current price of 41.43 is above the 20-day moving average (MA) of 39.70, above the 50-day MA of 38.99, and above the 200-day MA of 29.68, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 58.09 is Neutral, neither overbought nor oversold. The STOCH value of 65.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BTSG.
BrightSpring Health Services, Inc. Risk Analysis
BrightSpring Health Services, Inc. disclosed 57 risk factors in its most recent earnings report. BrightSpring Health Services, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BrightSpring Health Services, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.53B | 27.10 | 12.48% | ― | 11.41% | 8.70% | |
70 Outperform | $2.92B | 133.88 | 3.34% | ― | 19.01% | 38.68% | |
69 Neutral | $7.47B | 47.25 | 4.25% | ― | 17.23% | ― | |
64 Neutral | $3.37B | -7.86 | -106.91% | ― | 50.67% | -578.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $362.82M | -0.63 | -75.47% | ― | -16.65% | -71.92% |
* Healthcare Sector Average
BTSG
BrightSpring Health Services, Inc.
41.43
22.92
123.82%
EVH
Evolent Health
3.25
-5.52
-62.94%
PGNY
Progyny
17.69
-4.31
-19.59%
PRVA
Privia Health Group
23.75
-1.21
-4.85%
HNGE
Hinge Health, Inc. Class A
42.76
2.60
6.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.